Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BLINDOPTOGEN

Financiado

Cerrado

Vision Restoration with optogenetic tools

Blindness is one of the most devastating conditions affecting the quality of life in developed countries, especially in Europe. No treatment is known today for retinal degenerative diseases, such as retinitis pigmentosa or macular... ver más

31/08/2012

45K€

Presupuesto del proyecto: 45K€

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

0.00€ | Lider

Proyectos interesantes

BFU2015-67139-R

Medical Technol...

Applied Physics

169K€ Cerrado

RODRESET

Medical Technol...

Applied Physics

2M€ Cerrado

OPTOGENRET

Medical Technol...

Applied Physics

1M€ Cerrado

BFU2008-04199

Medical Technol...

Applied Physics

191K€ Cerrado

OPTISTIM

Medical Technol...

Applied Physics

2M€ Cerrado

LIIT-ChR2

Medical Technol...

Applied Physics

159K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 45K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Blindness is one of the most devastating conditions affecting the quality of life in developed countries, especially in Europe. No treatment is known today for retinal degenerative diseases, such as retinitis pigmentosa or macular degeneration. They are hereditary diseases characterized by the progressive loss of photoreceptors, leading to complete blindness. Recent discoveries of optical neuromodulators, such as channelrhodopsin-2 (ChR2) or halorhodopsin (NpHR), have opened up new possibilities of treating these diseases by imparting light-sensitivity to the remaining retinal neurons after the photoreceptors have died. During my previous Marie Curie postdoctoral fellowship, I have shown in a proof-of-concept study that this approach is feasible. We used a mouse model of retinal degeneration (rd1) and introduced ChR2 specifically in ON bipolar cells of the retina, upon which the animal regained retinal light responses, light-guided behavior, and form vision. Here, I propose to test several optogenetic strategies of treating blindness. This includes the use of several different mouse models for retinal degeneration, in appreciation of the fact that degenerative diseases are very diverse and a single approach might not work for different conditions. For each model organism, I will test the effectiveness of rendering different cell types light sensitive with optogenetic tools. Examples include bipolar cells and subsets thereof, and ganglion cells. The optogenetic tools I will use include ChR2 which activates neurons upon light stimulation, and NpHR, which hyperpolarizes neurons. The success of vision restoration will be tested and quantified at many levels, starting from the cellular level in the retina, to verify proper expression of the neuromodulator, to the circuitry level, to quantify the restoration of functional retinal properties, to the level of behavior, to establish if the animal regains visual guided behavior and form vision.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores